These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 31423250)

  • 61. Poor prognosis for hepatocellular carcinoma with transarterial chemoembolization pre-transplantation: retrospective analysis.
    Li HL; Ji WB; Zhao R; Duan WD; Chen YW; Wang XQ; Yu Q; Luo Y; Dong JH
    World J Gastroenterol; 2015 Mar; 21(12):3599-606. PubMed ID: 25834326
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The effect of postoperative TACE on prognosis of HCC with microscopic venous invasion.
    Ke-Wei L; Tian-Fu W; Xi L; Lü-Nan Y; Bo L; Yong Z; Wu-Sheng L; Wen-Tao W; Ming-Qing X; Jia-Yin Y; Yu-Kui M; Zhe-Yu C
    Hepatogastroenterology; 2012 Sep; 59(118):1944-6. PubMed ID: 22246191
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Prognosis of patients with hepatocellular carcinoma treated solely with transcatheter arterial chemoembolization: risk factors for one-year recurrence and two-year mortality (preliminary data).
    Matsuda M; Omata F; Fuwa S; Saida Y; Suzuki S; Uemura M; Ishii N; Iizuka Y; Fukuda K; Fujita Y
    Intern Med; 2013; 52(8):847-53. PubMed ID: 23583987
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Adjuvant transarterial chemoembolization timing after radical resection is an independent prognostic factor for patients with hepatocellular carcinoma.
    Sun H; Wang H; Wang Y; Zhong W; Meng Y; Lv Z; Guo W; Han B
    Front Oncol; 2023; 13():1129065. PubMed ID: 36969018
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Preoperative transarterial chemoembolization and resection for hepatocellular carcinoma: a nationwide Taiwan database analysis of long-term outcome predictors.
    Shi HY; Wang SN; Wang SC; Chuang SC; Chen CM; Lee KT
    J Surg Oncol; 2014 Apr; 109(5):487-93. PubMed ID: 24293372
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Platelet-to-Lymphocyte Ratio and Large Tumor Size Predict Microvascular Invasion after Resection for Hepatocellular Carcinoma.
    Rungsakulkij N; Mingphruedhi S; Suragul W; Tangtawee P; Muangkaew P; Aeesoa S
    Asian Pac J Cancer Prev; 2018 Dec; 19(12):3435-3441. PubMed ID: 30583666
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Transarterial chemoembolization versus surgery/radiofrequency ablation for recurrent hepatocellular carcinoma with or without microvascular invasion.
    Jin YJ; Lee JW; Lee OH; Chung HJ; Kim YS; Lee JI; Cho SG; Jeon YS; Lee KY; Ahn SI; Shin WY
    J Gastroenterol Hepatol; 2014 May; 29(5):1056-64. PubMed ID: 24372785
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Surgery combined with post-operative trancatheter arterial chemoembolization improves survival of intermediate hepatocellular carcinoma.
    Yi PS; Li Y; Yan S; Wu B; Lan C; Li JS
    Scand J Gastroenterol; 2019 Feb; 54(2):240-245. PubMed ID: 30880503
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Effects of antiviral therapy on hepatitis B virus reactivation and liver function after resection or chemoembolization for hepatocellular carcinoma.
    Lao XM; Luo G; Ye LT; Luo C; Shi M; Wang D; Guo R; Chen M; Li S; Lin X; Yuan Y
    Liver Int; 2013 Apr; 33(4):595-604. PubMed ID: 23402625
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Chemoembolization of recurrent hepatoma after curative resection: prognostic factors.
    Zu QQ; Liu S; Zhou CG; Yang ZQ; Xia JG; Zhao LB; Shi HB
    AJR Am J Roentgenol; 2015 Jun; 204(6):1322-8. PubMed ID: 26001244
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Clinicopathologic features of hepatocellular carcinoma patients surviving more than 10 years after radical hepatectomy].
    Wu LQ; Wang ZS; Cao JY; Hu WY; Han B; Sun CD; Zhang BY; Qiu FB; Zhang S; Yang JY; Cui ZJ
    Zhonghua Wai Ke Za Zhi; 2017 Feb; 55(2):130-135. PubMed ID: 28162213
    [No Abstract]   [Full Text] [Related]  

  • 72. Combined transcatheter arterial chemoembolization and radiofrequency ablation in single-session for solitary hepatocellular carcinoma larger than 7 cm.
    Yan JY; Zhang JL; Wang MQ; Yuan K; Bai YH; Wang Y; Xin HN; Wang ZJ; Liu FY; Duan F; Fu JX
    Asia Pac J Clin Oncol; 2018 Aug; 14(4):300-309. PubMed ID: 29124894
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Baseline quantitative hepatitis B core antibody could strongly predict survival for patients with hepatocellular carcinoma undergoing transarterial chemoembolization.
    Yuan G; Zhou Y; Zhang H; Wang J; Yang N; Guo Y; Yang D; Zhou Y
    Int J Clin Exp Med; 2015; 8(8):13524-31. PubMed ID: 26550290
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Predicting Infiltrative Hepatocellular Carcinoma Patient Outcome Post-TACE: MR Bias Field Correction Effect on 3D-quantitative Image Analysis.
    Liu C; Smolka S; Papademetris X; Minh DD; Gan G; Deng Y; Lin M; Chapiro J; Wang X; Georgiades C; Hong K
    J Clin Transl Hepatol; 2020 Sep; 8(3):292-298. PubMed ID: 33083252
    [No Abstract]   [Full Text] [Related]  

  • 75. Number of Nodules but not Size of Hepatocellular Carcinoma Can Predict Refractoriness to Transarterial Chemoembolization and Poor Prognosis.
    Katayama K; Imai T; Abe Y; Nawa T; Maeda N; Nakanishi K; Wada H; Fukui K; Ito Y; Yokota I; Ohkawa K
    J Clin Med Res; 2018 Oct; 10(10):765-771. PubMed ID: 30214648
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Clinical value of prophylactic transcatheter arterial chemoembolization treatment in patients with hepatocellular carcinoma.
    Li H; Liu Z; Han C
    Am J Transl Res; 2022; 14(5):3225-3232. PubMed ID: 35702096
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Circulating Cell-Free mtDNA Content as a Non-invasive Prognostic Biomarker in HCC Patients Receiving TACE and Traditional Chinese Medicine.
    Zhou G; Li Y; Li S; Liu H; Xu F; Lai X; Zhang Q; Xu J; Wan S
    Front Genet; 2021; 12():719451. PubMed ID: 34603382
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Combination of psoas muscle mass index and neutrophil/lymphocyte ratio as a prognostic predictor for patients undergoing nonsurgical hepatocellular carcinoma therapy.
    Sugama Y; Miyanishi K; Osuga T; Tanaka S; Hamaguchi K; Ito R; Sakamoto H; Kubo T; Ohnuma H; Murase K; Takada K; Kobune M; Kato J
    JGH Open; 2021 Dec; 5(12):1335-1343. PubMed ID: 34950776
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Effect of HBsAg expression in liver tissue on prognosis of hepatocellular carcinoma after minimally invasive interventional therapy.
    Liu B; Wang Q; Mei T; Zheng J; Gao W; Yuan C; Li K; Zhang Y
    Front Oncol; 2023; 13():1106333. PubMed ID: 36969054
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Fibrinogen/Lymphocyte Count Ratio Can Be Used as a New Indicator of Prognosis in Patients with Hepatocellular Carcinoma After Radical Resection.
    Li Y; Li Z; Deng K; Liao M; Yuan S; Huang Z
    Cancer Manag Res; 2020; 12():9057-9066. PubMed ID: 33061600
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.